NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
NTLA - Intellia Therapeutics, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$23.50
DETAILS
HIGH:
$49.00
LOW:
$9.00
MEDIAN:
$21.00
CONSENSUS:
$23.50
UPSIDE:
98.15%
Stock News
A New CRISPR "DNA Shredder" Could Change Gene-Editing -- What It Means for CRISPR Therapeutics
Gene-editing is a handy tool for developing sophisticated medicines. A new CRISPR molecule can destroy cells that express specific signals.
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on July 1, 2026, it awarded inducement grants to thirteen new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.
Wall Street Thinks This High-Flying Biotech Stock Can Soar Another 57%
It might pull it off, provided several things fall right in place.
Powder Keg Stocks: 10 Most‑Shorted Names Primed For A Monster Squeeze
Fresh short‑interest data for late June shows a tightly packed group of mid‑ and large‑cap names where bearish positioning has reached extreme territory, setting the stage for violent moves if sentiment flips.
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Intellia Therapeutics is leveraging its strategic partnership with Regeneron to advance a deep pipeline of CRISPR-based gene editing therapies. Omeros recently entered the commercial stage with the FDA approval of Yartemlea and a significant development deal with Novo Nordisk.
Dow Extends Record Run as Fed Decision Looms
Stocks are mixed, with the Dow Jones Industrial Average (DJI) trading at fresh record highs once again
This Stock Is Up 58% This Year. Is It too Late to Buy?
There could be additional catalysts for this drugmaker over the next year.
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Intellia's One-Time Gene Editing Therapy Gains Ground Against Rivals In Rare Swelling Disorder
Intellia Therapeutics, Inc. (NASDAQ:NTLA) stock is trading higher on Monday on additional positive findings from its global Phase 3 HAELO trial evaluating lonvo-z, its investigational CRISPR-based treatment for hereditary angioedema (HAE).
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
CAMBRIDGE, Mass., June 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today presented additional positive results from the global Phase 3 HAELO clinical trial of lonvo-z (formerly NTLA-2002) for hereditary angioedema (HAE) in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026 in Istanbul, Türkiye. Results from the trial were simultaneously published in the New England Journal of Medicine. The presentation and publication can be accessed from the Scientific Publications and Presentations section of intelliatx.com.
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock?
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., June 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on June 1, 2026, it awarded inducement grants to six new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026
CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that data from the global Phase 3 HAELO clinical trial of lonvo-z (formerly known as NTLA-2002) in hereditary angioedema (HAE) will be presented in a late-breaking oral presentation at the European Academy of Allergy & Clinical Immunology (EAACI) Annual Congress 2026, taking place June 12-15 in Istanbul, Türkiye. Intellia will also have a poster presentation detailing the burdens experienced by HAE patients living outside the United States.
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 data met all endpoints with an 87% attack reduction, but market reaction was muted due to safety concerns and the competitive landscape. The FDA lifted clinical holds on Nex-Z Phase 3 trials, enabling advancement in a $16.8bn ATTR market with a differentiated one-time treatment profile.
ADMA vs Intellia Therapeutics: Which Biotech Stock Is a Better Pick Now?
NTLA gains momentum after positive phase III data for its CRISPR therapy, while ADMA faces pricing and inventory pressure in IG markets.
Can Intellia's Pipeline Push Drive Long-Term Growth Amid Rivalry?
NTLA advances late-stage studies for nex-z and starts FDA filing for lonvo-z, positioning its pipeline for potential long-term growth.
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
Price Targets
Intellia Therapeutics downgraded to Underperform from Peer Perform at Wolfe Research
$9.00
(was $13.04)
Andy Chen
·
Wolfe Research
Intellia Therapeutics price target raised to $17 from $12 at Wedbush
$17.00
(was $14.71)
Wedbush
H.C. Wainwright Reiterates Buy Rating on Intellia Therapeutics (NTLA)
$25.00
(was $12.11)
New Street
Intellia Therapeutics price target raised to $17 from $13 at Bernstein
$17.00
(was $13.99)
Bernstein
Intellia Therapeutics price target lowered to $49 from $58 at Canaccord
$49.00
(was $14.42)
Canaccord Genuity
Intellia Therapeutics price target raised to $30 from $27 at Chardan
$30.00
(was $13.03)
Chardan Capital
Intellia Therapeutics price target raised to $35 from $29 at Leerink
$35.00
(was $13.21)
Leerink Partners
Intellia Therapeutics price target raised to $15 from $11 at Morgan Stanley
$15.00
(was $14.07)
Morgan Stanley
Intellia Therapeutics price target raised to $13 from $7 at Baird
$13.00
(was $13.94)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics (NTLA) PT Raised to $25 at H.C. Wainwright
$25.00
(was $13.95)
KeyBanc
Intellia Therapeutics (NTLA) PT Raised to $7 at Baird
$7.00
(was $14.39)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics downgraded to In Line from Outperform at Evercore ISI
$8.00
(was $9.73)
Evercore ISI
Intellia Therapeutics price target lowered to $14 from $25 at Truist
$14.00
(was $9.91)
Truist Financial
Intellia Therapeutics price target lowered to $27 from $33 at Oppenheimer
$27.00
(was $9.87)
Oppenheimer
Intellia Therapeutics price target lowered to $9 from $14 at Wedbush
$9.00
(was $12.49)
David Nierengarten
·
Wedbush
Intellia Therapeutics price target lowered to $18 from $25 at H.C. Wainwright
$18.00
(was $13.12)
Mitchell Kapoor
·
H.C. Wainwright
Intellia Therapeutics (NTLA) PT Lowered to $9 at Baird
$9.00
(was $13.12)
Jack Allen
·
Robert W. Baird
Intellia Therapeutics price target lowered to $29 from $33 at Citizens JMP
$29.00
(was $14.79)
JMP Securities
Intellia Therapeutics downgraded to Market Perform from Outperform at Bernstein
$14.50
(was $14.79)
Bernstein
Intellia Therapeutics price target lowered to $24 from $26 at Barclays
$24.00
(was $14.79)
Gena Wang
·
Barclays